Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 400

1.

A historical perspective on the discovery and elucidation of the hepatitis B virus.

Block TM, Alter HJ, London WT, Bray M.

Antiviral Res. 2016 Jul;131:109-23. doi: 10.1016/j.antiviral.2016.04.012. Epub 2016 Apr 20.

PMID:
27107897
2.

Hepatitis B knowledge among key stakeholders in Haimen City, China: Implications for addressing chronic HBV infection.

Cohen C, Evans AA, Huang P, London WT, Block JM, Chen G.

Hepatol Med Policy. 2016 Apr 14;1:4. doi: 10.1186/s41124-016-0004-x. eCollection 2016.

3.

Liver Cancer.

Gelband H, Chen CJ, Chen W, Franceschi S, Hall SA, London WT, McGlynn KA, Wild CP.

In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2015 Nov 1. Chapter 8.

4.

Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.

McMahon B, Block J, Block T, Cohen C, Evans AA, Hosangadi A, London WT, Sherman M; 2015 Princeton HCC Workshop participants.

J Natl Cancer Inst. 2015 Nov 30;108(4). pii: djv359. doi: 10.1093/jnci/djv359. Print 2016 Apr.

5.

Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

McGlynn KA, Petrick JL, London WT.

Clin Liver Dis. 2015 May;19(2):223-38. doi: 10.1016/j.cld.2015.01.001. Epub 2015 Feb 26. Review.

6.

Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink.

McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, Sahasrabuddhe VV.

J Natl Cancer Inst. 2015 Feb 26;107(4). pii: djv009. doi: 10.1093/jnci/djv009. Print 2015 Apr.

7.

Prevention of perinatal hepatitis B transmission in Haimen City, China: Results of a community public health initiative.

Evans AA, Cohen C, Huang P, Qian L, London WT, Block JM, Chen G.

Vaccine. 2015 Jun 12;33(26):3010-5. doi: 10.1016/j.vaccine.2015.01.054. Epub 2015 Feb 16.

8.

Chronic HBV infection outside treatment guidelines: is treatment needed?

Evans AA, London WT, Gish RG, Cohen C, Block TM.

Antivir Ther. 2013;18(2):229-35. doi: 10.3851/IMP2325. Epub 2012 Aug 23.

PMID:
22914436
9.

Can propranalol prevent hepatocellular carcinoma?

London WT, McGlynn KA.

Cancer Prev Res (Phila). 2012 Aug;5(8):989-91. doi: 10.1158/1940-6207.CAPR-12-0247.

10.

Dichlorodiphenyltrichloroethane and risk of hepatocellular carcinoma.

Persson EC, Graubard BI, Evans AA, London WT, Weber JP, LeBlanc A, Chen G, Lin W, McGlynn KA.

Int J Cancer. 2012 Nov 1;131(9):2078-84. doi: 10.1002/ijc.27459. Epub 2012 Mar 15.

11.

Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.

Nie H, Evans AA, London WT, Block TM, Ren XD.

J Hepatol. 2012 Apr;56(4):795-802. doi: 10.1016/j.jhep.2011.11.012. Epub 2011 Dec 13.

12.

International liver cancer incidence trends--letter.

McGlynn KA, London WT.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):384-5; author reply 386. doi: 10.1158/1055-9965.EPI-11-1102. Epub 2011 Dec 14. No abstract available.

13.

Fumonisin B1 and risk of hepatocellular carcinoma in two Chinese cohorts.

Persson EC, Sewram V, Evans AA, London WT, Volkwyn Y, Shen YJ, Van Zyl JA, Chen G, Lin W, Shephard GS, Taylor PR, Fan JH, Dawsey SM, Qiao YL, McGlynn KA, Abnet CC.

Food Chem Toxicol. 2012 Mar;50(3-4):679-83. doi: 10.1016/j.fct.2011.11.029. Epub 2011 Nov 29.

14.

Hepatocellular carcinoma of the liver.

Block T, Mehta AS, London WT.

Cancer Biomark. 2010;9(1-6):375-83. doi: 10.3233/CBM-2011-0165. Review.

PMID:
22112485
15.

Chronic hepatitis B infection: a workshop consensus statement and algorithm.

McHugh JA, Cullison S, Apuzzio J, Block JM, Cohen C, Leong SL, London WT, McNellis RJ, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ.

J Fam Pract. 2011 Sep;60(9):E1-8. Review.

PMID:
21901174
16.

Hepatitis B virus in the United States.

Evans AA, Cohen C, London WT.

Ann Intern Med. 2011 Aug 2;155(3):205; author reply 205-6. doi: 10.7326/0003-4819-155-3-201108020-00021. No abstract available.

PMID:
21810720
17.

The Australia antigen and role of the late Philadelphia General Hospital in reducing post-transfusion hepatitis and sequelae.

Senior JR, London WT, Sutnick AI.

Hepatology. 2011 Sep 2;54(3):753-6. doi: 10.1002/hep.24593.

PMID:
21809361
18.

The global epidemiology of hepatocellular carcinoma: present and future.

McGlynn KA, London WT.

Clin Liver Dis. 2011 May;15(2):223-43, vii-x. doi: 10.1016/j.cld.2011.03.006. Review.

19.

Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis.

Nie H, Evans AA, London WT, Block TM, Ren XD.

J Clin Virol. 2011 Aug;51(4):234-40. doi: 10.1016/j.jcv.2011.05.020. Epub 2011 Jun 12.

20.

Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach.

Nie H, Evans AA, London WT, Block TM, Ren XD.

J Clin Microbiol. 2011 Jul;49(7):2440-8. doi: 10.1128/JCM.02472-10. Epub 2011 May 11.

21.

Is chronic hepatitis B being undertreated in the United States?

Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM.

J Viral Hepat. 2011 Jun;18(6):377-83. doi: 10.1111/j.1365-2893.2010.01401.x. Epub 2010 Dec 8. Review.

PMID:
21143343
22.

Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.

Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB, McMahon BJ; Hepatitis B Foundation.

Hepatology. 2010 Dec;52(6):2192-205. doi: 10.1002/hep.23934. Epub 2010 Oct 1.

PMID:
20890947
23.

Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B.

Haber BA, Block JM, Jonas MM, Karpen SJ, London WT, McMahon BJ, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB; Hepatitis B Foundation.

Pediatrics. 2009 Nov;124(5):e1007-13. doi: 10.1542/peds.2009-0567. Epub 2009 Oct 5.

PMID:
19805457
24.

The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop.

Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD.

Cancer Biomark. 2008;4(1):19-33. Review.

PMID:
18334731
25.

Underestimation of chronic hepatitis B virus infection in the United States of America.

Cohen C, Evans AA, London WT, Block J, Conti M, Block T.

J Viral Hepat. 2008 Jan;15(1):12-3. No abstract available.

26.

Blood folate levels and risk of liver damage and hepatocellular carcinoma in a prospective high-risk cohort.

Welzel TM, Katki HA, Sakoda LC, Evans AA, London WT, Chen G, O'Broin S, Shen FM, Lin WY, McGlynn KA.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1279-82.

27.

Acculturation and breast density in foreign-born, U.S. Chinese women.

Tseng M, Byrne C, Evers KA, London WT, Daly MB.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1301-5.

28.

Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.

Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA.

Am J Gastroenterol. 2006 Aug;101(8):1797-803. Epub 2006 Jun 30.

PMID:
16817842
29.

Epidemiology and natural history of hepatocellular carcinoma.

McGlynn KA, London WT.

Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23. Review.

PMID:
15757802
30.

Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China.

Sakoda LC, Graubard BI, Evans AA, London WT, Lin WY, Shen FM, McGlynn KA.

Int J Cancer. 2005 Jul 1;115(4):618-24.

31.

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study.

Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA.

Int J Epidemiol. 2005 Feb;34(1):132-7. Epub 2005 Jan 19.

PMID:
15659459
32.

Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans.

Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, Mehta AS.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84. Epub 2005 Jan 10.

33.

Surrogate markers of efficacy for medical treatment of viral hepatitis.

Block TM, London WT.

Biotechnol Healthc. 2004 Oct;1(5):42-8.

34.

Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status.

Comunale MA, Mattu TS, Lowman MA, Evans AA, London WT, Semmes OJ, Ward M, Drake R, Romano PR, Steel LF, Block TM, Mehta A.

Proteomics. 2004 Mar;4(3):826-38.

PMID:
14997503
35.

Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population.

Harris RA, Chen G, Lin WY, Shen FM, London WT, Evans AA.

Cancer Causes Control. 2003 Dec;14(10):995-1000.

PMID:
14750539
36.

Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers.

Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S, London WT, Evans AA.

J Med Virol. 2004 Jan;72(1):35-40.

PMID:
14635008
37.

Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans.

McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, Shen FM, Evans AA, London WT, Buetow KH.

Cancer Res. 2003 Aug 1;63(15):4594-601.

38.

A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma.

Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, Dwek R, Block TM.

Proteomics. 2003 May;3(5):601-9.

PMID:
12748940
39.

A phylogenetic analysis identifies heterogeneity among hepatocellular carcinomas.

McGlynn KA, Edmonson MN, Michielli RA, London WT, Lin WY, Chen GC, Shen FM, Buetow KH.

Hepatology. 2002 Dec;36(6):1341-8.

PMID:
12447857
40.

Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences.

Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76.

41.

A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma.

Steel LF, Mattu TS, Mehta A, Hebestreit H, Dwek R, Evans AA, London WT, Block T.

Dis Markers. 2001;17(3):179-89. Review.

42.

Cholecystokinin and gastrin levels are not elevated in human pancreatic adenocarcinoma.

Weinberg DS, Heyt GJ, Cavanagh M, Pitchon D, McGlynn KA, London WT.

Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):721-2. No abstract available.

43.

Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1.

Balsara BR, Pei J, De Rienzo A, Simon D, Tosolini A, Lu YY, Shen FM, Fan X, Lin WY, Buetow KH, London WT, Testa JR.

Genes Chromosomes Cancer. 2001 Mar;30(3):245-53. Review.

PMID:
11170281
44.

Hepatitis B vaccine and liver problems in U.S. children less than 6 years old.

Evans AA, London WT.

Epidemiology. 1999 Nov;10(6):790-1. No abstract available.

PMID:
10535806
45.

Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma.

Evans AA, O'Connell AP, Pugh JC, Mason WS, Shen FM, Chen GC, Lin WY, Dia A, M'Boup S, Dramé B, London WT.

Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):559-65.

46.

Do Asian HBV carriers differ from non-Asian carriers?

Evans AA, Fine MK, London WT.

Lancet. 1998 Apr 25;351(9111):1285-6. No abstract available.

PMID:
9643771
47.
48.

A case of self-experimentation.

London NL, London WT.

Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):475-6. No abstract available.

49.

Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis.

Zhou T, Evans AA, London WT, Xia X, Zou H, Shen F, Clapper ML.

Cancer Res. 1997 Jul 1;57(13):2749-53.

50.

The epidemiology of hepatitis viruses B, C, and D.

London WT, Evans AA.

Clin Lab Med. 1996 Jun;16(2):251-71. Review.

PMID:
8792071

Supplemental Content

Loading ...
Support Center